chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Accidental underdose
Clinical narrative: administered 0.3mL; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (administered 0.3mL) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jun-2021, the patient experienced ACCIDENTAL UNDERDOSE (administered 0.3mL). At the time of the report, ACCIDENTAL UNDERDOSE (administered 0.3mL) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment given and no symptoms reported. Pharmacist would like to know if there is any course of action to be taken. Consent for the follow up given
Sex: M
Vaccine: COVID19
Symptoms: Cough
Clinical narrative: Cough after vaccination; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough after vaccination) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, the patient experienced COUGH (Cough after vaccination). At the time of the report, COUGH (Cough after vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided. No treatment information was provided.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Loss of personal independence in daily activities, Malaise, Pyrexia
Clinical narrative: Loss of personal independence in daily activities; sleepiness; Feeling unwell; dizziness; fever; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness) and PYREXIA (fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities ), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness), PYREXIA (fever) and FATIGUE (tiredness). At the time of the report, LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities ), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness), PYREXIA (fever) and FATIGUE (tiredness) outcome was unknown.            No Concomitant medications were reported. No treatment medications were reported. Action taken with mRNA-1273 in response to the events were Not Applicable.   This case was linked to MOD-2021-044406 (Patient Link).
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Somnolence
Clinical narrative: Loss of personal independence in daily activities; sleepiness; Feeling unwell; dizziness; fever; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness) and PYREXIA (fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities ), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness), PYREXIA (fever) and FATIGUE (tiredness). At the time of the report, LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Loss of personal independence in daily activities ), SOMNOLENCE (sleepiness), MALAISE (Feeling unwell ), DIZZINESS (dizziness), PYREXIA (fever) and FATIGUE (tiredness) outcome was unknown.            No Concomitant medications were reported. No treatment medications were reported. Action taken with mRNA-1273 in response to the events were Not Applicable.   This case was linked to MOD-2021-044406 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Possible administration of expired vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Possible administration of expired vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Possible administration of expired vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Possible administration of expired vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.   Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Anosmia
Clinical narrative: my bowel movement has almost no smell; This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (my bowel movement has almost no smell) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ANOSMIA (my bowel movement has almost no smell). At the time of the report, ANOSMIA (my bowel movement has almost no smell) outcome was unknown.            Concomitant roduct use was not provided.  Treatment information was not provided.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Sore Arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Sore Arm) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included ATORVASTATIN, METOPROLOL, ASPIRIN [ACETYLSALICYLIC ACID], VITAMIN D3, MULTIVITAMIN [VITAMINS NOS] and FLUOROURACIL for an unknown indication.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced INJECTION SITE PAIN (Sore Arm). At the time of the report, INJECTION SITE PAIN (Sore Arm) outcome was unknown.            No treatment medications were provided. Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-033059 (Patient Link).
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash pruritic
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pruritic rash (itchy rash on arm) and rash (itchy rash on back, stomach and waistline) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 030L20A) for COVID-19 immunization. No medical history reported. On Jan 31, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced pruritic rash (itchy rash on arm) and rash (itchy rash on back, stomach and waistline). Patient treated with triamcinolone 1% for rash. At the time of the report, pruritic rash (itchy rash on arm) and rash (itchy rash on back, stomach and waistline) outcome: unknown. Concomitant medication list not provided. Action taken with mRNA-1273 in response to events: not applicable. This case linked to MOD-2021-023725 (patient link).
Sex: F
Vaccine: COVID19
Symptoms: Pleurisy
Clinical narrative: Pleurisy; This spontaneous case was reported by a consumer and describes the occurrence of PLEURISY (Pleurisy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PLEURISY (Pleurisy). The patient was treated with IBUPROFEN for Pleurisy, at an unspecified dose and frequency. At the time of the report, PLEURISY (Pleurisy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Sex: U
Vaccine: COVID19
Symptoms: Anosmia
Clinical narrative: my bowel movement has almost no smell; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (my bowel movement has almost no smell) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ANOSMIA (my bowel movement has almost no smell). At the time of the report, ANOSMIA (my bowel movement has almost no smell) outcome was unknown.            No concomitant medications were provided.  No treatment medications were provided.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Only received one dose/ not received her second dose because she feels she missed the call to schedule; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Only received one dose/ not received her second dose because she feels she missed the call to schedule) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis (bad arthritis and would not move very well).    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Only received one dose/ not received her second dose because she feels she missed the call to schedule). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Only received one dose/ not received her second dose because she feels she missed the call to schedule) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported by the reporter.  Treatment medication was not provided by the reporter.  The patient did not have her second dose as of 02-Jul-2021.   Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Follow up report received included information about current condition: The patient did not have any adverse event after first dose and was doing fine.
Sex: F
Vaccine: COVID19
Symptoms: Limb discomfort, Peripheral swelling
Clinical narrative: she has had serious problems with her feet and legs ever since; both of her feet and legs swelled up; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up). At the time of the report, LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment information was reported.        Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Correspondence email letter - TCR received where Patient identifier (gender) and event has been reported.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal discomfort
Clinical narrative: big knot in throat, left of adams apple; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL DISCOMFORT (big knot in throat, left of adams apple) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced OROPHARYNGEAL DISCOMFORT (big knot in throat, left of adams apple). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 06-Feb-2021, OROPHARYNGEAL DISCOMFORT (big knot in throat, left of adams apple) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The Patient went to the Doctor and the doctor could not figure it out. No Concomitant medications were reported. The patient had taken steroid.   This case was linked to MOD-2021-038759 (Patient Link).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: On 03-May-2021, follow up document was attached in which the outcome of the events is recovered.
Sex: F
Vaccine: COVID19
Symptoms: Injection related reaction, Product dose omission issue
Clinical narrative: Instant reaction to the vaccine; missed second dose-She was advised not to take the second dose of the moderna vaccine.; This spontaneous case was reported by a nurse and describes the occurrence of INJECTION RELATED REACTION (Instant reaction to the vaccine) and PRODUCT DOSE OMISSION ISSUE (missed second dose-She was advised not to take the second dose of the moderna vaccine.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced INJECTION RELATED REACTION (Instant reaction to the vaccine) and PRODUCT DOSE OMISSION ISSUE (missed second dose-She was advised not to take the second dose of the moderna vaccine.). At the time of the report, INJECTION RELATED REACTION (Instant reaction to the vaccine) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (missed second dose-She was advised not to take the second dose of the moderna vaccine.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient was advised not to take the second dose of the vaccine.  Patient still wants to be vaccinated, and want s to know is she can take the Pfizer vaccine.  No Concomitant medications reported. No treatment medications reported.
Sex: F
Vaccine: COVID19
Symptoms: Illness
Clinical narrative: she heard that 2 other people were sick after the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (she heard that 2 other people were sick after the vaccine) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ILLNESS (she heard that 2 other people were sick after the vaccine). At the time of the report, ILLNESS (she heard that 2 other people were sick after the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment details were reported.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: TCR received on 06-JUL-2021 to contact through mail ID provided, On 28-Jul-2021: Followup received included pt gender,age group and intials were updated.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Sore muscles; Fever; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Sore muscles) and PYREXIA (Fever) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in 2020.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Dec-2020, the patient experienced MYALGIA (Sore muscles) and PYREXIA (Fever). The patient was treated with IBUPROFEN for Adverse event, at a dose of 1 UNK. At the time of the report, MYALGIA (Sore muscles) and PYREXIA (Fever) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medications included Flonase.   This case was linked to MOD-2021-046419 (Patient Link).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Asthenia, Fatigue, Hypersomnia, Vomiting
Clinical narrative: sick in stomach; slept all Sunday morning and all afternoon; Does not have the energy level she had prior Covid; vommitting; Extremely tired; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (sick in stomach), HYPERSOMNIA (slept all Sunday morning and all afternoon), ASTHENIA (Does not have the energy level she had prior Covid), VOMITING (vommitting) and FATIGUE (Extremely tired) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, the patient experienced ABDOMINAL DISCOMFORT (sick in stomach), HYPERSOMNIA (slept all Sunday morning and all afternoon), ASTHENIA (Does not have the energy level she had prior Covid), VOMITING (vommitting) and FATIGUE (Extremely tired). At the time of the report, ABDOMINAL DISCOMFORT (sick in stomach), HYPERSOMNIA (slept all Sunday morning and all afternoon), ASTHENIA (Does not have the energy level she had prior Covid), VOMITING (vommitting) and FATIGUE (Extremely tired) outcome was unknown.            No Concomitant medication was provided by the Reporter. No Treatment Information was provided by the Reporter. he patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the mRNA-1273 in response to the events was not applicable.
Sex: U
Vaccine: COVID19
Symptoms: Dizziness, Vomiting
Clinical narrative: dizzy; feel like throwing up; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy) and VOMITING (feel like throwing up) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (dizzy) and VOMITING (feel like throwing up). At the time of the report, DIZZINESS (dizzy) and VOMITING (feel like throwing up) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   Reporter did not allow further contact
Age: 51.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Erythema, Flushing, Infusion site pain, Rhinorrhoea, Thrombophlebitis superficial
Clinical narrative: Superficial vein thrombosis; weight gain; Runny nose; legs were shaking; Flushing; face, ears and chest began to become red; Pain on her arm/pain was in the same area she gets her IV infusion; This spontaneous case was reported by an other health care professional and describes the occurrence of THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis), INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion), RHINORRHEA (Runny nose), TREMOR (legs were shaking) and FLUSHING (Flushing) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product AGALSIDASE BETA for Fabry's disease.    No Medical History information was reported.   On 04-Jan-2021, the patient started AGALSIDASE BETA (Intravenous) 70 milligram every two weeks. On 17-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced RHINORRHEA (Runny nose), TREMOR (legs were shaking), FLUSHING (Flushing) and ERYTHEMA (face, ears and chest began to become red). On 15-Feb-2021, the patient experienced WEIGHT INCREASED (weight gain). In 2021, the patient experienced INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion). On an unknown date, the patient experienced THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis). At the time of the report, THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis) and INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion) was resolving, RHINORRHEA (Runny nose), TREMOR (legs were shaking), FLUSHING (Flushing) and ERYTHEMA (face, ears and chest began to become red) had resolved and WEIGHT INCREASED (weight gain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment Medication was not provided.
Age: 51.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Tremor, Weight increased
Clinical narrative: Superficial vein thrombosis; weight gain; Runny nose; legs were shaking; Flushing; face, ears and chest began to become red; Pain on her arm/pain was in the same area she gets her IV infusion; This spontaneous case was reported by an other health care professional and describes the occurrence of THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis), INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion), RHINORRHEA (Runny nose), TREMOR (legs were shaking) and FLUSHING (Flushing) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product AGALSIDASE BETA for Fabry's disease.    No Medical History information was reported.   On 04-Jan-2021, the patient started AGALSIDASE BETA (Intravenous) 70 milligram every two weeks. On 17-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced RHINORRHEA (Runny nose), TREMOR (legs were shaking), FLUSHING (Flushing) and ERYTHEMA (face, ears and chest began to become red). On 15-Feb-2021, the patient experienced WEIGHT INCREASED (weight gain). In 2021, the patient experienced INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion). On an unknown date, the patient experienced THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis). At the time of the report, THROMBOPHLEBITIS SUPERFICIAL (Superficial vein thrombosis) and INFUSION SITE PAIN (Pain on her arm/pain was in the same area she gets her IV infusion) was resolving, RHINORRHEA (Runny nose), TREMOR (legs were shaking), FLUSHING (Flushing) and ERYTHEMA (face, ears and chest began to become red) had resolved and WEIGHT INCREASED (weight gain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment Medication was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Limb discomfort, Peripheral swelling
Clinical narrative: she has had serious problems with her feet and legs ever since; both of her feet and legs swelled up; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up). At the time of the report, LIMB DISCOMFORT (she has had serious problems with her feet and legs ever since) and PERIPHERAL SWELLING (both of her feet and legs swelled up) outcome was unknown.            Concomitant medication were not provided. Treatment details were not provided.   This case was linked to MOD-2021-219904 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Correspondence email response attached no new information
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of MYALGIA, HEADACHE and CHILLS in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, the patient experienced MYALGIA, HEADACHE and CHILLS. The patient was treated with ACETAMINOPHEN ongoing from 06-Feb-2021 at an unspecified dose and frequency. On 07-Feb-2021, MYALGIA and CHILLS had resolved. On 09-Feb-2021, HEADACHE had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitants included medication for diabetes, hypertension medication, not specified.  No treatment medications were reported.   This case was linked to MOD-2021-031189 (Patient Link).
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore arm for about 4 days; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm for about 4 days) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high (under control), Sclerosis multiple (under control Patient goes in every 6 weeks for an infusion for his Multiple Sclerosis.) and Cholesterol (under control).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm for about 4 days). At the time of the report, PAIN IN EXTREMITY (sore arm for about 4 days) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication were high blood pressure, and high cholesterol for his Multiple Sclerosis. No treatment information was provided.   This case was linked to MOD-2021-046071.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up received on 14 JULY 2021 and event updated.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Injection site bruising, Injection site rash, Myalgia, Nausea
Clinical narrative: Swollen Arm; Arm Hurt; Bruise at site of shot; muscle aches; Rash in arm; Body Chills; Nausea; Fever; This spontaneous case was reported by a patient and describes the occurrence of PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches) and INJECTION SITE RASH (Rash in arm) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001C21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Hypersensitivity. Previously administered products included for an unreported indication: Influenza (reaction- high fever for several days, throwing up and body aches) in 2014. Concurrent medical conditions included Autoimmune hypothyroidism since 2018, Hashimoto's disease since 2018, Fatigue (Using energy med from doctor (started in last few weeks)) since 2020, Chronic sinusitis since 2008, Skin rash (Poison ivy spread and blistered over a month over both arms) since 04-Jun-2021, Skin rash (tick bite caused rash for up to 6 inches for about a week) since 28-May-2021, Drug allergy and Drug allergy. Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (ORTHO TRI-CYCLEN) for Birth control, LEVOTHYROXINE for Thyroid disorder NOS.   On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches), INJECTION SITE RASH (Rash in arm), CHILLS (Body Chills), NAUSEA (Nausea) and PYREXIA (Fever). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches), INJECTION SITE RASH (Rash in arm), CHILLS (Body Chills), NAUSEA (Nausea) and PYREXIA (Fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Ice pack and cream for rash were used for treatment.   This case was linked to MOD-2021-118796 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Non-Significant Follow up Appended - NNI.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Peripheral swelling, Pyrexia
Clinical narrative: Swollen Arm; Arm Hurt; Bruise at site of shot; muscle aches; Rash in arm; Body Chills; Nausea; Fever; This spontaneous case was reported by a patient and describes the occurrence of PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches) and INJECTION SITE RASH (Rash in arm) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001C21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Hypersensitivity. Previously administered products included for an unreported indication: Influenza (reaction- high fever for several days, throwing up and body aches) in 2014. Concurrent medical conditions included Autoimmune hypothyroidism since 2018, Hashimoto's disease since 2018, Fatigue (Using energy med from doctor (started in last few weeks)) since 2020, Chronic sinusitis since 2008, Skin rash (Poison ivy spread and blistered over a month over both arms) since 04-Jun-2021, Skin rash (tick bite caused rash for up to 6 inches for about a week) since 28-May-2021, Drug allergy and Drug allergy. Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (ORTHO TRI-CYCLEN) for Birth control, LEVOTHYROXINE for Thyroid disorder NOS.   On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches), INJECTION SITE RASH (Rash in arm), CHILLS (Body Chills), NAUSEA (Nausea) and PYREXIA (Fever). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, PERIPHERAL SWELLING (Swollen Arm), PAIN IN EXTREMITY (Arm Hurt), INJECTION SITE BRUISING (Bruise at site of shot), MYALGIA (muscle aches), INJECTION SITE RASH (Rash in arm), CHILLS (Body Chills), NAUSEA (Nausea) and PYREXIA (Fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Ice pack and cream for rash were used for treatment.   This case was linked to MOD-2021-118796 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Non-Significant Follow up Appended - NNI.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia
Clinical narrative: Hair thinning at the top of her head; Hair loss; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (Hair loss) and ALOPECIA (Hair thinning at the top of her head) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, the patient experienced ALOPECIA (Hair loss). On an unknown date, the patient experienced ALOPECIA (Hair thinning at the top of her head). At the time of the report, ALOPECIA (Hair loss) and ALOPECIA (Hair thinning at the top of her head) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication were not provided. Treatment medication were not provided.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Injection site warmth
Clinical narrative: Arm was hot; slight headache; This spontaneous case was reported by a health care professional and describes the occurrence of INJECTION SITE WARMTH (Arm was hot) and HEADACHE (slight headache) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE WARMTH (Arm was hot) and HEADACHE (slight headache). At the time of the report, INJECTION SITE WARMTH (Arm was hot) and HEADACHE (slight headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Treatment medication was not provided.  Patients were taking anti-anxiety medication.   This case was linked to MOD-2021-041229, MOD-2021-041229.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Confusional state, Dizziness, Fatigue, Hunger, Lymphadenopathy
Clinical narrative: Extreme swollen lymph node; Hungry feel; Fatigued, Get tired; Nausea; Dizziness; Confusion; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 02-Jun-2021 and was forwarded to Moderna on 02-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion), LYMPHADENOPATHY (Extreme swollen lymph node), HUNGER (Hungry feel) and FATIGUE (Fatigued, Get tired) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy, Sulfonamide allergy and Drug allergy (Allergic to Iodine). Concomitant products included COLECALCIFEROL (VITAMIN D 3), UBIDECARENONE (COQ 10), GINKGO BILOBA and NATTOKINASE for an unknown indication.    On 30-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, the patient experienced DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion) and NAUSEA (Nausea). On 01-Apr-2021, the patient experienced LYMPHADENOPATHY (Extreme swollen lymph node), HUNGER (Hungry feel) and FATIGUE (Fatigued, Get tired). At the time of the report, DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion), HUNGER (Hungry feel), FATIGUE (Fatigued, Get tired) and NAUSEA (Nausea) outcome was unknown and LYMPHADENOPATHY (Extreme swollen lymph node) had not resolved. Not Provided          No treatment information was provided by reporter.   This case was linked to MOD-2021-219973, MOD-2021-041181 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Jun-2021: Additional Information has ADR form with patient medical history,  conmed, 2nd dose ivaccine nformation,
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Extreme swollen lymph node; Hungry feel; Fatigued, Get tired; Nausea; Dizziness; Confusion; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 02-Jun-2021 and was forwarded to Moderna on 02-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion), LYMPHADENOPATHY (Extreme swollen lymph node), HUNGER (Hungry feel) and FATIGUE (Fatigued, Get tired) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy, Sulfonamide allergy and Drug allergy (Allergic to Iodine). Concomitant products included COLECALCIFEROL (VITAMIN D 3), UBIDECARENONE (COQ 10), GINKGO BILOBA and NATTOKINASE for an unknown indication.    On 30-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, the patient experienced DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion) and NAUSEA (Nausea). On 01-Apr-2021, the patient experienced LYMPHADENOPATHY (Extreme swollen lymph node), HUNGER (Hungry feel) and FATIGUE (Fatigued, Get tired). At the time of the report, DIZZINESS (Dizziness), CONFUSIONAL STATE (Confusion), HUNGER (Hungry feel), FATIGUE (Fatigued, Get tired) and NAUSEA (Nausea) outcome was unknown and LYMPHADENOPATHY (Extreme swollen lymph node) had not resolved. Not Provided          No treatment information was provided by reporter.   This case was linked to MOD-2021-219973, MOD-2021-041181 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Jun-2021: Additional Information has ADR form with patient medical history,  conmed, 2nd dose ivaccine nformation,
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Head discomfort, Illness
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), ILLNESS (has been sick) and HEAD DISCOMFORT (head congestion) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 021B21A and 046B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On 02-Jun-2021, the patient experienced ILLNESS (has been sick) and HEAD DISCOMFORT (head congestion). On 11-Jun-2021, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) had not resolved and ILLNESS (has been sick) and HEAD DISCOMFORT (head congestion) was resolving.            Concomitant medication information was not provided.  Treatment information was not provided.
Sex: F
Vaccine: COVID19, UNK
Symptoms: Contusion, Headache, Pain in extremity
Clinical narrative: Limb Contusion; Pain of extremities; Headache; This spontaneous case was reported by a physician and describes the occurrence of CONTUSION (Limb Contusion), PAIN IN EXTREMITY (Pain of extremities) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced CONTUSION (Limb Contusion), PAIN IN EXTREMITY (Pain of extremities) and HEADACHE (Headache). At the time of the report, CONTUSION (Limb Contusion), PAIN IN EXTREMITY (Pain of extremities) and HEADACHE (Headache) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment medication was not provided.   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth
Clinical narrative: Is dry mouth a side affect; This spontaneous case was reported by a consumer and describes the occurrence of DRY MOUTH (Is dry mouth a side affect) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, the patient experienced DRY MOUTH (Is dry mouth a side affect). At the time of the report, DRY MOUTH (Is dry mouth a side affect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Alopecia
Clinical narrative: hair loss; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (hair loss) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ALOPECIA (hair loss). At the time of the report, ALOPECIA (hair loss) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (hair loss) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ALOPECIA (hair loss). At the time of the report, ALOPECIA (hair loss) outcome was unknown.          No concomitant medication was reported. Treatment medication was not provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was not applicable.   Reporter did not allow further contact   Reporter did not allow further contact
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: 15 year old female who received her first dose of the Moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old female who received her first dose of the Moderna vaccine) in a 15-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old female who received her first dose of the Moderna vaccine). On 11-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old female who received her first dose of the Moderna vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was provided.